type 2 diabetes

Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Drug Delivery Business News
Novo Nordisk
diabetes
type 2 diabetes
Europe
Ozempic
Flag link:
Spread of diabetes in the world: state of the art
Spread of diabetes in the world: state of the art
GoinPharma
type 2 diabetes
IQVIA
Flag link:
Novo gains FDA OK for semaglutide
Novo gains FDA OK for semaglutide
BioPharma Dive
Novo Nordisk
semaglutide
FDA
Ozempic
type 2 diabetes
Flag link:
Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD
Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD
NASDAQ.com
Jardiance
Eli Lilly
type 2 diabetes
PAD
Flag link:
Cost of diabetes epidemic reaches $850 billion a year
Cost of diabetes epidemic reaches $850 billion a year
Yahoo/Reuters
diabetes
type 2 diabetes
Flag link:
Regulus reports a trio of pipeline setbacks
Regulus reports a trio of pipeline setbacks
BioPharma Dive
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C
Flag link:
Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data
Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data
Motley Fool
JNJ
Invokana
type 2 diabetes
Flag link:
FDA Adds Boxed Warning to Janssen's Type 2 Diabetes Drug Label
FDA Adds Boxed Warning to Janssen's Type 2 Diabetes Drug Label
RAPS.org
FDA
Janssen
type 2 diabetes
warnings
Invokana
Invokamet
Flag link:
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Mass Device
Novo Nordisk
Xultophy
diabetes
type 2 diabetes
insulin degludec
liraglutide
Flag link:
MannKind Hopes To Reverse Fortunes With Television Show
MannKind Hopes To Reverse Fortunes With Television Show
Seeking Alpha
MannKind
television ads
diabetes
type 2 diabetes
DTC advertising
Flag link:
Virta Health looks to reverse, not treat, Type II diabetes
Virta Health looks to reverse, not treat, Type II diabetes
Drug Delivery Business News
Virta Health
type 2 diabetes
diabetes
devices
patients
mobile apps
Flag link:
Merck, Pfizer line up a big FDA decision on a blockbuster hopeful, staring down some major league competition
Merck, Pfizer line up a big FDA decision on a blockbuster hopeful, staring down some major league competition
Endpoints
Merck
Pfizer
FDA
ertugliflozin
diabetes
type 2 diabetes
Flag link:
J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study
J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study
Mass Device
JNJ
Ethicon
devices
type 2 diabetes
bariatric surgery
Flag link:
FDA Clears New Tool for Patients with Type 2 Diabetes
FDA Clears New Tool for Patients with Type 2 Diabetes
Qmed
diabetes
FDA
JNJ
type 2 diabetes
LifeScan
blood glucose monitoring
WellDoc
Flag link:
Lilly Shares Spike On Jardiance Approval (LLY)
Lilly Shares Spike On Jardiance Approval (LLY)
Investopedia
Eli Lilly
FDA
Jardiance
type 2 diabetes
cardiovascular death
Flag link:
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
Market Realist
JNJ
FDA
type 2 diabetes
diabetes
Invokamet XR
Janssen
Flag link:
U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults
U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults
Yahoo
diabetes
Synjardy
type 2 diabetes
Flag link:
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
Yahoo
type 2 diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Flag link:
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
Yahoo
AstraZeneca
Bydureon
clinical trials
diabetes
type 2 diabetes
Flag link:

Pages